Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
about
Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.
P2860
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@en
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@nl
type
label
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@en
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@nl
prefLabel
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@en
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@nl
P2093
P356
P1476
Pharmacokinetics and inhibitor ...... ticipated in the CASTLE Study.
@en
P2093
Anna Persson
Awny Farajallah
Donnie McGrath
Heather Sevinsky
Jean-Michel Molina
Jenny Zhang
Mark Krystal
Michael Child
Richard Bertz
P304
P356
10.1093/JAC/DKR490
P407
P577
2011-11-25T00:00:00Z